Changes To Antidepressant Black Box On Suicide Recommended By FDA Panel
Executive Summary
FDA's findings that the suicidality risk with antidepressants does not extend beyond young adults should be added to the current "black box" warning on pediatric suicidality, the Psychopharmacologic Drugs Advisory Committee says
You may also be interested in...
Cymbalta Fibromyalgia Approval Sets Another REMS Precedent
FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides
Cymbalta Fibromyalgia Approval Sets Another REMS Precedent
FDA's approval of Lilly's Cymbalta (duloxetine) for treatment of fibromyalgia sets another precedent in the new era of Risk Evaluation and Mitigation Strategies: the agency will not necessarily seek a formal REMS for products already accompanied by mandatory medication guides
FDA Probes How To Compile Clinical Trial Data; Legal, Scientific Barriers Remain
Despite having gathered large amounts of clinical trial data through the years, FDA faces challenges when it comes to analyzing the data outside of the original scope in which it was collected